Free-text search
Articles per year:
Content Types
-
Spago plans stock market exit to facilitate fundraising
Swedish research company Spago Nanomedical plans to apply to delist from Nasdaq First North.
-
Pfizer job cuts reported at several manufacturing sites
Pfizer has previously announced a major cost-cutting programme. Now, reports have emerged of job losses at several of the pharmaceutical giant's manufacturing sites in Europe and the US.
-
Inossia raises SEK 88m – targets US approval
The Swedish medtech company Inossia, which is developing an additive for bone cement, has completed an oversubscribed SEK 88 million share issue.
-
Moderna plunged by double digits after study data leaked
Biotech company Moderna fell nearly 18 percent on the stock market after study data on the company’s mRNA-based cancer vaccine spread on social media ahead of the planned presentation.
-
EQT leads €9.6bn buyout of Qiagen
Swedish investment firm EQT is poised to make a major acquisition in the diagnostics sector with a 9.6 billion euro bid for Dutch company Qiagen.
-
AstraZeneca wins new FDA approval for serious kidney disease
A new treatment indication has opened up for AstraZeneca’s Ultomiris following positive results from a phase III trial. The FDA has approved the drug for a rare kidney disease, although its long-term clinical benefits have yet to be established.
-
Anna Rennermalm: Are we hiring the best candidate – or the best AI user?
When AI is used both to write and screen job applications, it is becoming increasingly difficult to assess what candidates can actually do. Could meeting in person become more important than ever? Anna Rennermalm explores the question in this column.
-
Major spin-off: Abbott plans to separate nutrition business
Abbott's global nutrition business generates approximately $8.5 billion in annual sales. Now, the medtech giant has announced plans to spin off the business into a separate, publicly traded company.
-
AstraZeneca's labor ward drug withdrawal is due to lack of commercial viability
The upcoming withdrawal of labor drug Bricanyl is based on commercial calculations rather than supply chain problems.
-
Sciety appoints Thomas Eldered as senior advisor
Life science investment firm Sciety has appointed entrepreneur and business leader Thomas Eldered as its new senior advisor.
-
Swedish firm makes progress on antiviral treatment
A compound developed by Swedish company Virenc has shown promising results against SARS-CoV-2 in an advanced model of human airways. The findings mark a step forward in efforts to develop a treatment that could act against multiple viruses.
-
New hair loss pill delivers positive Phase 3 results
A new tablet formulation of a drug originally developed to treat high blood pressure has shown promising results against hereditary hair loss.
-
GLP-1 drugs spark unexpected interest among perfume giants
The appetite-suppressing effects of weight-loss drugs are well known. But could they also change what people want to smell like? That question has now caught the attention of some of the world's biggest perfume manufacturers.
-
Roche doubles down on Chinese biotech in deal worth up to $15 billion
A year after their first antibody-drug conjugate deal, Roche and China’s Hansoh Pharmaceutical are expanding their partnership. The new agreement covers several cancer programmes and could bring Hansoh more than $15 billion in payments.
-
Saniona moves depression drug closer to first-in-human trial
The Swedish-Danish research company Saniona has submitted an application to the FDA to begin testing its oral drug candidate in patients with major depressive disorder.
-
Merck KGAA to acquire Silence Therapeutics for billions
German pharmaceutical and chemical group Merck KGAA has entered into an agreement to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion, equivalent to SEK 12.9 billion.
-
Former Novo Nordisk CEO nominated as Lundbeck chair
Lars Fruergaard Jørgensen, former CEO of Novo Nordisk, has been nominated to become the new Chair of the Board at Lundbeck. He is expected to succeed Dorothea Wenzel, who has informed the Board of her intention to step down.
-
China seeks to block foreign acquisitions of biotech platforms
The Chinese government plans to introduce new rules to restrict foreign companies’ ability to acquire Chinese biotechnology.
-
A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”
For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes and every milestone matters? Ahead of Pharma Outsourcing – Find the Right Partner in Stockholm on 2 December, we spoke with conference moderator Pernille Hemmingsen, CTO at Adcendo, about the challenges of working with external development partners.
-
Ulf Landegren: From scientific discovery to successful companies
He is a scientist, inventor and entrepreneur with a string of successful companies to his name. Now, Ulf Landegren, a professor at Uppsala University, is to receive a newly established award – in memory of a kindred spirit.
-
Lilly’s new weight-loss pill recommended for EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued several new recommendations on medicines, including Eli Lilly’s Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and the treatment of type 2 diabetes in adults.
-
Danish health minister: Europe must act on China
Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Minister Ida Auken also warns that Europe must act to keep pace with growing competition from China.
-
AstraZeneca strikes 1.5 billion dollar AI drug discovery deal
AstraZeneca is entering into a strategic collaboration with US-based AI company insitro to identify novel drug targets and develop treatments for difficult-to-treat metabolic and heart muscle diseases.
-
EMA backs Revolution’s pancreatic cancer drug after rapid review
A new drug that has shown very promising results in metastatic pancreatic cancer has been recommended for approval in the EU following a record-fast review process.
BREAKING